Status:
COMPLETED
The Addition of Whole Grains to the Diets of Adults: A Study of Digestive Health and Natural Defenses
Lead Sponsor:
Tufts University
Collaborating Sponsors:
General Mills
Tufts Medical Center
Conditions:
Digestive Health and Immune Function
Eligibility:
All Genders
40-65 years
Phase:
NA
Brief Summary
The purpose of this study is to determine if substituting whole grains for refined grains in the diets of healthy adults over a period of 6 weeks alters the composition of the bacteria in the gut, and...
Detailed Description
This study is a randomized parallel-arm trial using a six-week dietary intervention following a 2 week run-in period. Healthy volunteers will be randomized to two groups (n=40/group), and consume eith...
Eligibility Criteria
Inclusion
- Subjects Inclusion Criteria
- Healthy male and female subjects aged 40-65 y (women must be \> 1 year postmenopausal or had both ovaries removed, if premenopausal).
- Body mass index (BMI) 20-35 kg/m.2
- Pass screening blood and urine tests
- Creatinine ≤ 1.5 mg/dL
- glutamic oxaloacetic transaminase/serum glutamate pyruvate transaminase/total bilirubin ≤ twice the upper limit of normal range
- Fasting glucose \<125 mg/dL
- hematocrit ≥ 32%
- white blood cell count ≥ 1.8 x 103/mm3 (M)
- PLT ≥ 100 x 103/mm3 (thou/µL)
- Must be willing to be randomized.
- Those randomized to either the WG or RG groups must be willing to consume only study foods and beverages provided.
- Exclusion Criteria
- Self reported weight change \>4kg within the past 3 months.
- Have participated in a weight loss program within the last 3-months; eligible if in weight reduction program to maintain body weight.
- Not willing to reduce habitual daily fiber intake (including prebiotics) within 2 wk prior to enrollment to \< \~7g/1000kcal/d for men, or \<\~8g/1000kcal/d for women if currently consuming greater amounts.
- Not willing to stop consumption of probiotic or prebiotic supplements within 2 weeks prior to start of study if currently taking these, as well as during study participation.
- Vegetarian diet.
- Not willing to stop taking multivitamins, and supplements (with the exception of vitamin D and calcium), including fish oil or n-3 fatty acids and herbal supplements, for 30 days prior to or during study participation, if currently taking these.
- Regular use of laxatives, stool softeners, or anti-diarrheal medications, and medications influencing food intake and/or appetite.
- Not willing to undergo a 3-month washout period after colonoscopy prior to enrollment, and not willing to defer colonoscopy until after study completion.
- Eating disorder within the past 10 years.
- Disinhibited eating behavior as indicated by a score above 12 on the Three Factor Eating Questionnaire.
- Food allergies or aversions or other issues with foods that would preclude use of study diets, including gluten, milk, nuts, or eggs.
- Individuals identified during screening as having barriers expected to deter compliance with dietary requirements (e.g., stated dislike of study foods, inadequate resources to store and reheat meals, inability to adhere to food pick-up schedule).
- Alcohol consumption \>2 drinks per day.
- Not willing to abstain from alcohol consumption during the study.
- Smoking or using nicotine containing products in the last 6 months.
- Use of aspirin, non-steroidal anti-inflammatory medications (NSAIDs) or antihistamine prescribed by a physician or clinician, or the inability to discontinue the use of these substances for 72 hrs before first day blood draw until 48 hrs after DTH implant (i.e. after second reading).
- Use of anabolic steroids, insulin, growth hormone or testosterone.
- Type I or type II diabetes.
- Uncontrolled major illnesses. (Will include if stable on drugs used to control cardiovascular, liver, and renal diseases, asthma, and dysphagia).
- Current use of proton pump inhibitors and H2 blockers to control acid-reflux/heart burn
- Use of medications which interfere with energy metabolism including oral glycemic agents and insulin.
- Uncontrolled hypertension as determined by study physician or nurse.
- Use of immunosuppressive drugs.
- Active cancer or current cancer diagnosis (except non-melanoma skin cancer).
- Active infection within 2 weeks of study enrollment, blood draws or skin tests; however, may participate if admission is postponed or study activity is rescheduled \> 2 weeks after resolution of symptoms.
- Any antibiotic use within the past 3 months, except topical antibiotic use.
- History of dysphagia, malabsorptive disorders, inflammatory bowel disease or other gastrointestinal disorders such as ulcerative colitis, Crohn's disease, celiac disease , chronic diarrhea or constipation.
- Gastric bypass or other surgery for weight loss.
- Splenectomy or partial splenectomy.
- Autoimmune diseases such as rheumatoid arthritis and psoriasis. Autoimmune thyroid disease that has been treated and with stable replacement doses is not an exclusion.
- Taking warfarin or coumadin any time during the previous 6 months.
- Current diagnosis of or treatment for psychosis (i.e. schizophrenia, etc.). Include depression if has been stable on treatment regimen for \> 6 months.
- Blindness or deafness not corrected with use of glasses and hearing aids.
- Does not speak English; due to insufficient funds to hire a translator and to get all study materials translated into another language to allow us to recruit non-English speaking participants non-English speakers will not be eligible to participate.
Exclusion
Key Trial Info
Start Date :
June 1 2012
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2014
Estimated Enrollment :
108 Patients enrolled
Trial Details
Trial ID
NCT01902394
Start Date
June 1 2012
End Date
September 1 2014
Last Update
May 21 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
HNCRA at Tufts University
Boston, Massachusetts, United States, 02111